You clearly have no idea about the potential of the B Cell platform if you’re genuinely suggesting it should be offload for $1 billion. It has two drugs in clinical trials and a further 5+ waiting in the background. At the current point in time it’s probably worth about $5 billion and that will grow past $10 billion once the first licensing deal is signed. Sure it’s not currently reflected in the share price but that’s not surprising given there’s still a high amount of risk discounting applied.
Selling the B Cell platform right now for such a small amount is not at all in shareholders interest nor will it speed up the CF33 and onCARlytics platforms which are almost certainly running as fast as the FDA will permit.
Just have some patience as the share price will likely improve throughout the year both in anticipation of and upon positive results as clinical trial progress is made throughout the year. As per company advice, I’m anticipating significant updates and milestones across all the platforms throughout the remainder of the year. Whilst it might seem like things are moving slowly, remember that Yuman Fong essentially described the progress of the CF33 platform as lightning quick!
IMU Price at posting:
13.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)